Mallinckrodt PLC shareholders lost their bid for an official committee to represent them in the drugmaker’s bankruptcy as it vies to dig out from an avalanche of litigation over opioid sales, WSJ Pro Bankruptcy reported. Bankruptcy Judge John Dorsey rejected the request yesterday, handing a win to Mallinckrodt, which is struggling to build support for a turnaround strategy that would resolve the company’s legal troubles. Like Purdue Pharma LP and Insys Therapeutics Inc., Mallinckrodt resorted to bankruptcy to try to get an agreement with states, municipalities, tribes and people seeking damages for the company’s alleged role in fueling the national epidemic of opioid addiction. In addition to opioid litigation, Mallinckrodt faces potential damages in an argument with the government over rebates to Medicaid for the company’s Acthar Gel product.
